HOME >> MEDICINE >> NEWS
Study examined switching rates between Allegra® (fexofenadine HCl) and Claritin®

CHICAGO, Il., November 13, 1999 - A higher percentage of seasonal allergic rhinitis (SAR) patients switched to Allegra® (fexofenadine HCl) from Claritin® (loratadine) than vice versa in the spring and fall of 1997 and 1998, according to the results of a study of more than 33,000 patients presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI).

The findings are based on "Prescribing Patterns of Non-sedating Antihistamines and Daily Dose Differences in a Managed Care Population," a study that evaluated the continuity of allergy treatment by drug and by allergy season (spring, fall 1997- 1998). The retrospective study analyzed data from physicians' claims from 12 United Healthcare health plans.

During the study period, an average of 12.6 percent of patients taking Claritin switched to Allegra versus 10.0 percent of patients who switched from Allegra to Claritin. "Usage data about newer therapies is important for managed care organizations to analyze so they can understand physician and patient preferences," said Lewis Roht, M.D., Director of Drug Surveillance and Epidemiology at Hoechst Marion Roussel.

Other Studies
Other data presented at the ACAAI meeting by Hoechst Marion Roussel included:

  • A four-week, multicenter, double-blind, randomized, placebo-controlled study which showed that Allegra at doses of 20, 60, 120, and 240 mg reduced pruritus and number of wheals scores over a four-week period for the treatment of chronic idiopathic urticaria (CIU), also known as hives. The study demonstrated that all doses of Allegra greatly reduced the symptoms compared to placebo (P0.0115). Additionally, patients who received Allegra experienced significantly less interference with sleep and daily activities than patients who received placebo (P0.0014). Twice-daily doses of 60 mg or greater were most effective. Adverse events occurred with similar incidence in all treatment groups, with
    '"/>


Contact: Suzanne Wiele
816-966-3475
Porter Novelli
12-Nov-1999


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, ... over 1,000 passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading ... it was time to refresh the carpeting with the goal of maintaining the ...
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning assistance that serves communities throughout southern Florida, is working to ... provide scholarship assets to children from low income families. , The Take Stock ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Aug. 8, 2017   ... diluted (GAAP) loss per share from continuing operations ... revenues increased 16 percent to $110 million ... 27 percent to $161 million ... from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
Cached News: